Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV.

摘要

Diffuse large B-cell lymphoma (DLBCL) is a disease marked by heterogeneity in clinical presentation, morphology, and underlying biology. Importantly, this translates into variability of patient response to chemotherapy. While a majority of patients can be cured effectively with modern chemotherapy regimens, many present with or acquire resistance to treatment. Characterizing the mechanism(s) responsible for poor patient outcome is critical for identifying future targets to improve treatment